BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

- October 6 YouTube premiere featuring Sway Calloway, Howard "H” White and leading medical and cultural voices anchors community education nationwide

PALO ALTO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the "Company” or "BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on genetic diseases, today announced a nationwide education effort with community partners to increase awareness of transthyretin amyloid cardiomyopathy, also called ATTR cardiac amyloidosis (ATTR-CM). ATTR-CM is an underrecognized cause of heart failure that occurs when TTR, a protein that plays an essential role in the transport of vitamin A and thyroxine, becomes unstable, breaks down and builds up in the heart, causing it to become thicker and stiffer and making it harder to pump blood effectively. Because symptoms may resemble more common heart conditions or be dismissed as normal aging, ATTR-CM can be overlooked or identified later in the disease journey.